PACS Group (NYSE:PACS) Director Mark Hancock Sells 144,318 Shares of Stock

PACS Group, Inc. (NYSE:PACS) Director Mark Hancock sold 144,318 shares of the stock in a transaction on Monday, September 14th. The shares were sold at an average price of $44.57, for a total value of $6,432,253.26. Following the sale, the director directly owned 53,674,566 shares in the company, valued at $2,392,275,406.62. This trade represents a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hancock also recently made the following trade(s):

• On Tuesday, September 15th, Mark Hancock sold 155,682 shares of PACS Group stock. The shares were sold at an average price of $42.47, for a total transaction of $6,611,814.54.
• On Thursday, July 9th, Mark Hancock sold 4,966 shares of PACS Group stock. The shares were sold at an average price of $45.06, for a total transaction of $223,767.96.
• On Wednesday, July 8th, Mark Hancock sold 20,338 shares of PACS Group stock. The shares were sold at an average price of $45.07, for a total transaction of $916,633.66.
• On Monday, July 6th, Mark Hancock sold 142,163 shares of PACS Group stock. The shares were sold at an average price of $45.33, for a total transaction of $6,444,248.79.
• On Thursday, July 2nd, Mark Hancock sold 12,825 shares of PACS Group stock. The stock was sold at an average price of $45.01, for a total transaction of $577,253.25.
• On Wednesday, July 1st, Mark Hancock sold 6,080 shares of PACS Group stock. The shares were sold at an average price of $45.02, for a total transaction of $273,721.60.
• On Friday, June 26th, Mark Hancock sold 61,931 shares of PACS Group stock. The stock was sold at an average price of $40.50, for a total value of $2,508,205.50.
• On Thursday, June 25th, Mark Hancock sold 138,069 shares of PACS Group stock. The shares were sold at an average price of $40.33, for a total value of $5,568,322.77.
• On Wednesday, June 17th, Mark Hancock sold 63,680 shares of PACS Group stock. The shares were sold at an average price of $35.31, for a total transaction of $2,248,540.80.

PACS Group Stock Down 5.7%

Shares of PACS stock opened at $42.01 on Wednesday. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.21. PACS Group, Inc. has a 12 month low of $10.31 and a 12 month high of $49.49. The stock has a market cap of $6.65 billion, a P/E ratio of 24.42, a P/E/G ratio of 1.39 and a beta of -0.13. The company has a 50 day simple moving average of $44.71 and a two-hundred day simple moving average of $39.13.

PACS Group (NYSE:PACS) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.09. The business had revenue of $1.43 billion for the quarter, compared to analysts’ expectations of $1.41 billion. PACS Group had a net margin of 4.85% and a return on equity of 29.55%. On average, research analysts expect that PACS Group, Inc. will post 2.13 earnings per share for the current year.

Key Headlines Impacting PACS Group

Here are the key news stories impacting PACS Group this week:

• Positive Sentiment: Wall Street remains constructive on PACS Group. Truist Financial, Oppenheimer, UBS, and JPMorgan have assigned price targets ranging from $57 to $62, while the reported consensus target is $58.80 versus recent trading levels. Analysts cite the company’s growth outlook and maintain an overall “Moderate Buy” rating. PACS Group insider trading and analyst coverage
• Positive Sentiment: The company’s latest quarterly results exceeded expectations, with earnings per share of $0.63 versus the $0.54 consensus estimate and revenue of $1.43 billion versus $1.41 billion expected. This supports the case for continued earnings growth in PACS Group’s skilled-nursing and post-acute-care operations.
• Neutral Sentiment: PACS Group presented at the 2026 Jefferies Healthcare Services and Technology Conference on September 15. Management discussed operations and its growth strategy, but the announcement did not disclose new financial guidance or a material business update. PACS Group Jefferies conference announcement
• Negative Sentiment: Director Mark Hancock sold 300,000 shares across September 14–15 for roughly $13.0 million, while CEO Jason Murray sold more than 10,000 shares in the latest reported transactions. The sales add near-term supply and may concern investors, although Hancock and Murray still retain more than 53 million and 54 million shares, respectively; the reported sales represent only small reductions in their holdings. PACS Group director insider sale filing

Hedge Funds Weigh In On PACS Group

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP increased its position in shares of PACS Group by 370.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 780,159 shares of the company’s stock valued at $25,051,000 after purchasing an additional 614,250 shares during the last quarter. 8 Knots Management LLC bought a new stake in PACS Group in the fourth quarter worth $23,421,000. Sei Investments Co. boosted its stake in PACS Group by 7.4% during the first quarter. Sei Investments Co. now owns 370,501 shares of the company’s stock worth $11,900,000 after buying an additional 25,462 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in PACS Group by 44.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 288,718 shares of the company’s stock worth $9,274,000 after buying an additional 89,067 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in PACS Group during the first quarter valued at $6,762,000.

Wall Street Analysts Forecast Growth

PACS has been the subject of several research analyst reports. Oppenheimer raised their price target on PACS Group from $48.00 to $57.00 and gave the company an “outperform” rating in a report on Monday, August 10th. JPMorgan Chase & Co. increased their target price on PACS Group from $47.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. Truist Financial set a $62.00 price target on shares of PACS Group in a research report on Wednesday, September 2nd. Royal Bank Of Canada upped their price target on shares of PACS Group from $52.00 to $57.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Finally, UBS Group increased their price objective on shares of PACS Group from $57.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, PACS Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $58.80.

About PACS Group

PACS Group, Inc is a U.S. healthcare services company that operates skilled nursing and post-acute care facilities. Its facilities provide short-term rehabilitation, long-term skilled nursing, nursing care, and related clinical services for patients recovering from illness, injury, surgery, or hospitalization.

The company’s broader care offerings may include assisted living, memory care, behavioral health, and other specialized post-acute services, depending on the facility and market.